Drugs / Evogam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00391131 | Apr 2007 → Oct 2009 | immunodeficiency disease | CSL Limited | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Evogam | “This phase III, open-label, multi-centre study investigated the efficacy, safety, pharmacokinetics and quality of life impact of Evogam(®), a new chromatographically...” PMID 22526590 ↗ Apr 2012 |
| Modality | Protein / enzyme biologic | “a new chromatographically fractionated 16% subcutaneous immunoglobulin” PMID 22526590 ↗ Apr 2012 |
| Route | Subcutaneous | “administered subcutaneously” NCT00391131 ↗ |